title: The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly.
abstract: This study compares the efficacy of telmisartan with that of valsartan and ramipril in reducing blood pressure (BP) over 24 hrs in the elderly patients with metabolic syndrome (MS). This prospective and open label study analyzed a sample of 60 patients over 65 years of age with hypertension and with MS. At the beginning the BP was monitored by a 24-hr ambulatory blood pressure monitoring (AMBP). Following this, the 60 patients were divided into 3 groups of 20, to each of which was prescribed, respectively, telmisartan, valsartan and ramipril to take for 12 weeks. The drugs were to be taken at 9.00 a.m. Later on the doses were increased. After 12 weeks of therapy, BP was monitored by a 24-hr AMBP. The use of telmisartan caused a greater reduction of the BP in the final 4-6 hours of the period between the 1st administration of the drug and the next one, these last 4-6 hours being those when cardiovascular and cerebrovascular accidents are more frequent (between 6.00 and 10.00 a.m.). Comparing to valsartan and ramipril, telmisartan results in excellent pressure control during the last 4-6 hours between the 1st administration of the drug and the next one.
authors.affiliation: Dipartimento di Scienze dell'Invecchiamento, Sapienza Universita di Roma, Umberto I Policlinico di Roma, Roma, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Formosa
authors.forename: A
authors.initials: A
authors.lastname: Bellomo
authors.forename: A
authors.initials: A
authors.lastname: Iori
authors.forename: V
authors.initials: V
authors.lastname: Gianturco
authors.forename: E
authors.initials: E
authors.lastname: D'Ottavio
authors.forename: M
authors.initials: M
authors.lastname: Mancinella
authors.forename: C
authors.initials: C
authors.lastname: Lo Iacono
authors.forename: G
authors.initials: G
authors.lastname: Troisi
authors.forename: V
authors.initials: V
authors.lastname: Marigliano
mesh_terms: D000367:Age Factors; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002940:Circadian Rhythm / Q000187:drug effects*; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011446:Prospective Studies; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan